CAJ | 학술논문

目的：：评价丁螺环酮治疗新型毒品所致精神障碍患者的临床疗效和安全性。方法：将80例符合CCMD--3诊断标准的伴有焦虑情绪的新型毒品所致精神障碍的住院患者，随机分为研究组和对照组。研究组40例患者应用抗焦虑药物丁螺环酮治疗()；对照组40例患者未使用抗焦虑药物治疗。两组患者均使用抗精神病药物利培酮治疗，疗程为4周。两组患者治疗前及治疗后第1、2、4周末采用汉密顿焦虑量表(HAMA)评定临床疗效，不良反应量表(TESS)评定不良反应。结果：组内比较，治疗第4周末，研究组与对照组患者的HAMA以及HAMA因子分与治疗前比较差异均有显著性(P<0.05)，显示两组患者的焦虑情绪均得到缓解；但研究组患者治疗第2周末HAMA以及HAMA因子分与治疗前比较差异即有显著性(P<0.05)，显示研究组起效快；且组间比较表明，研究组患者治疗第4周末疗效优于对照组(P<0.01)，显示研究组焦虑缓解明显。不良反应方面，两组患者比较差异无显著性(P>0.05)。结论：丁螺环酮治疗新型毒品所致精神障碍住院患者焦虑情绪有效，不良反应轻微。
목적：：평개정라배동치료신형독품소치정신장애환자적림상료효화안전성。방법：장80례부합CCMD--3진단표준적반유초필정서적신형독품소치정신장애적주원환자，수궤분위연구조화대조조。연구조40례환자응용항초필약물정라배동치료()；대조조40례환자미사용항초필약물치료。량조환자균사용항정신병약물리배동치료，료정위4주。량조환자치료전급치료후제1、2、4주말채용한밀돈초필량표(HAMA)평정림상료효，불량반응량표(TESS)평정불량반응。결과：조내비교，치료제4주말，연구조여대조조환자적HAMA이급HAMA인자분여치료전비교차이균유현저성(P<0.05)，현시량조환자적초필정서균득도완해；단연구조환자치료제2주말HAMA이급HAMA인자분여치료전비교차이즉유현저성(P<0.05)，현시연구조기효쾌；차조간비교표명，연구조환자치료제4주말료효우우대조조(P<0.01)，현시연구조초필완해명현。불량반응방면，량조환자비교차이무현저성(P>0.05)。결론：정라배동치료신형독품소치정신장애주원환자초필정서유효，불량반응경미。
Objective:To investigate clinical efficacy and safety of Buspirone in treatment of patients with new-type drug-in-duced mental disorders. Methods:80 hospitalized patients diagnosed with the new-type drug-induced mental disorders accompanied by anxiety according to CCMD-3 were randomly assigned to study group (40 cases, treated with Buspirone for 4 weeks) and control group (40 cases, treated without antianxiety drugs for 4 weeks). The Hamilton anxiety scale (HAMA) was used to assess the clinical efficacy, while the treatment emergent symptom scale ( TESS) was used to evaluate the adverse reactions at baseline, 1, 2, and 4 weeks after the treatment. Results:According to the in-group comparison, the HAMA scores and HAMA factor scores 4 weeks after the treatment were significantly different from those at baseline in both study group and control group (P<0. 05), showing that anxiety in the two groups was in remission. But the HAMA scores and HAMA factor scores 2 weeks after the treatment had been significantly different from those at baseline in study group (P<0. 05), showing that study group had improved more rapidly. The between-group comparison showed that there were better treatment effects in study group that in control group 4 weeks after the treatment (P<0. 01), showing that anxiety in study groups was in remission obviously. There were no significant difference in adverse reactions between the two groups (P>0. 05). Conclusions:Buspirone is effective in the treatment of the hospitalized patients with new-type drug-induced mental disorders with mild adverse reactions.